RT期刊文章SR电子T1供体表面活性剂蛋白A2多态性和肺移植生存JF欧洲呼吸杂志JO EUR RESSIR J FD欧洲呼吸协会SP 1900618 DO 10.1183/13993003.00618-2019188bet官网地址Aramini，Beatrice A1 Lederer，David A1 Diangelo，Susan L. A1 Arcasoy，Selim A1 Sonett，Joshua R. A1 Robbins，Hillary A1 Shah，Lory A1 Costa，Joseph A1 Urso，Andreacarola Yr 2020 ul HTTP：//2020 ul HTTP：////////erernals。com/content/55/3/1900618.表面活性剂蛋白的吸收AB目的基因多态性，肺部先天免疫的主要参与者与各种肺部疾病有关。这项研究的目的是研究表面活性剂蛋白（SP）内变异之间的潜在关联 - 供体肺同种异体移植物和移植后的受体。方法是肺移植患者（n = 192）是前瞻性的。带有肺功能测试，带有支气管肺泡灌洗和活检的支气管镜检查。使用焦磷酸测序法测定供体肺SP-A1（6AN）和SP-A2（1AN）基因多态性。报告了未经调整和调整后的分层COX存活模型。SP-A1和SP-A2基因型频率以及肺移植受者和供体特征以及死亡原因。每个供体SP-A2变体分组。从SP-A2 1A0（n = 102）的供体接收肺的个体与1A1变体（n = 68）或SP-A2基因型1A01A0（n = 54）对1A0A1（n = 38）的人（n = 38）的生存率更大（1年）（1年）（log-rank p <0.025）。对于SP-A1变体没有明显的关联。1年生存和诊断的分层调整后的生存模型显示1A1变体和1A01A1基因型的生存率降低。 Furthermore, when survival was conditional on 1-year survival no significance was observed, indicating that the survival difference was due to the first year's outcome associated with the 1A1 variant.Conclusion Donor lung SP-A gene polymorphisms are associated with post-transplant clinical outcome. Lungs from donors with the SP-A2 variant 1A1 had a reduced survival at 1 year. The observed donor genetic differences, via innate immunity relate to the post-transplant clinical outcome.Donor genetic polymorphisms of the lung-specific innate defence systems determine post-lung transplant recipient outcome http://bit.ly/2QNpX7Q